{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:30Z","timestamp":1786120290604,"version":"build-2736575974"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/icu.0b013e32834bbe91","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T19:56:21Z","timestamp":1317758181000},"page":"508-516","source":"Crossref","is-referenced-by-count":45,"title":["Ocular Beh\u00e7et disease"],"prefix":"10.1097","volume":"22","author":[{"given":"Cem","family":"Evereklioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210206","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of Behcet disease.","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R2-13-20210206","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-4632.2006.02754.x","article-title":"Clinical features of Behcets disease in children.","volume":"45","author":"Borlu","year":"2006","journal-title":"Int J Dermatol"},{"key":"R3-13-20210206","first-page":"50","article-title":"Increased nitric oxide production in patients with Behcets disease: is it a new activity marker J Am Acad D","volume":"46","author":"Evereklioglu","year":"2002","journal-title":"ermatol"},{"key":"R4-13-20210206","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2133.2002.04703.x","article-title":"Serum leptin concentration is increased in patients with Behcets syndrome and is correlated with disease activity.","volume":"147","author":"Evereklioglu","year":"2002","journal-title":"Br J Dermatol"},{"key":"R5-13-20210206","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/09629350310001599710","article-title":"The pathophysiological significance of red blood cell nitric oxide concentrations in inflammatory Behcets disease.","volume":"12","author":"Evereklioglu","year":"2003","journal-title":"Mediators Inflamm"},{"key":"R6-13-20210206","first-page":"246","article-title":"Urinary nitric oxide levels are increased and correlated with plasma concentrations in patients with Behcets disease: is it a new urinary activity marker N","volume":"8","author":"Evereklioglu","year":"2003","journal-title":"ephrology"},{"key":"R7-13-20210206","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1046\/j.1365-4362.2003.01688.x","article-title":"Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcets syndrome.","volume":"42","author":"Cekmen","year":"2003","journal-title":"Int J Dermatol"},{"key":"R8-13-20210206","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1155\/MI.2005.237","article-title":"Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Behcets syndrome.","volume":"4","author":"Turkoz","year":"2005","journal-title":"Mediators Inflamm"},{"key":"R9-13-20210206","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000051544","article-title":"Increased plasma adrenomedullin levels in patients with Behcets disease.","volume":"201","author":"Evereklioglu","year":"2000","journal-title":"Dermatology"},{"key":"R10-13-20210206","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1442-2042.2002.00468.x","article-title":"Urinary adrenomedullin levels are increased and correlated with plasma concentrations in patients with Behcets syndrome.","volume":"9","author":"Evereklioglu","year":"2002","journal-title":"Int J Urol"},{"key":"R11-13-20210206","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/bjo.86.6.653","article-title":"Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behcets disease.","volume":"86","author":"Er","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R12-13-20210206","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/0962935031000097754","article-title":"Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behcets disease.","volume":"12","author":"Erkilic","year":"2003","journal-title":"Mediators Inflamm"},{"key":"R13-13-20210206","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/bjo.2005.076836","article-title":"The 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism in Behcets patients with or without ocular involvement.","volume":"89","author":"Ozkul","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R14-13-20210206","first-page":"653","article-title":"Behcets disease and vitiligo in two brothers: coincidence or association Clin Exp D","volume":"34","author":"Borlu","year":"2009","journal-title":"ermatol"},{"key":"R15-13-20210206","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1468-3083.2004.00547.x","article-title":"The significance of immunohistochemistry in the skin pathergy reaction of patients with Behcets syndrome.","volume":"18","author":"Inaloz","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R16-13-20210206","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s004080000019","article-title":"Thoracic involvement in Behcets disease and its correlation with multiple parameters.","volume":"178","author":"Gunen","year":"2000","journal-title":"Lung"},{"key":"R17-13-20210206","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1258\/0022215011908946","article-title":"Audio-vestibular evaluation in patients with Behcets syndrome.","volume":"115","author":"Evereklioglu","year":"2001","journal-title":"J Laryngol Otol"},{"key":"R18-13-20210206","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/112067210201200105","article-title":"Increased corneal thickness in active Behcets disease.","volume":"12","author":"Evereklioglu","year":"2002","journal-title":"Eur J Ophthalmol"},{"key":"R19-13-20210206","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1046\/j.1468-3083.2003.00760.x","article-title":"Stressful life events, anxiety, depression and coping mechanisms in patients with Behcets disease.","volume":"17","author":"Karlidag","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R20-13-20210206","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/pgmj.2003.017756","article-title":"Neurotologic status in Behcets disease and its ophthalmologic correlates.","volume":"80","author":"Bayazit","year":"2004","journal-title":"Postgrad Med J"},{"key":"R21-13-20210206","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10067-004-1015-3","article-title":"Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behcets disease.","volume":"24","author":"Duygulu","year":"2005","journal-title":"Clin Rheumatol"},{"key":"R22-13-20210206","first-page":"1152","article-title":"On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus.","volume":"105","author":"Behcet","year":"1937","journal-title":"Dermatol Wochenschr"},{"key":"R23-13-20210206","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.3748\/wjg.v12.i35.5748","article-title":"Diagnostic dilemma between intestinal Behcet disease and inflammatory bowel disease with pyoderma gangrenosum.","volume":"12","author":"Evereklioglu","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R24-13-20210206","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1601-0825.2006.01298.x","article-title":"Regarding the naming dilemma of Behcet disease in the 21st century.","volume":"13","author":"Evereklioglu","year":"2007","journal-title":"Oral Dis"},{"key":"R25-13-20210206","first-page":"1078","article-title":"Criteria for diagnosis of Behcets disease.","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"R26-13-20210206","first-page":"506","article-title":"Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcets disease: a multicenter study.","volume":"16","year":"1989","journal-title":"J Rheumatol"},{"key":"R27-13-20210206","first-page":"328","article-title":"The migration pattern, patient selection with diagnostic methodological flaw and confusing naming dilemma in Behcet disease.","volume":"143","author":"Evereklioglu","year":"2007","journal-title":"Eur J Echocardiogr"},{"key":"R28-13-20210206","first-page":"136","article-title":"Behcets disease or Adamantiades-Behcet disease An evidence-based historical survey.","volume":"16","author":"Evereklioglu","year":"2010","journal-title":"Med Sci Monit"},{"key":"R29-13-20210206","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/14656566.5.2.317","article-title":"Managing the symptoms of Behcets disease.","volume":"5","author":"Evereklioglu","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"R30-13-20210206","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09629350220131935","article-title":"Serum levels of TNF-, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcets disease.","volume":"11","author":"Evereklioglu","year":"2002","journal-title":"Mediators Inflamm"},{"key":"R31-13-20210206","doi-asserted-by":"crossref","first-page":"1034Education","DOI":"10.1136\/bjo.2007.127522","article-title":"Sustained remission after infliximab in a child with systemic vasculitis refractory to conventional immunosuppressive therapy including interferon-.","volume":"92","author":"Evereklioglu","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R32-13-20210206","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Behcets disease.","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"R33-13-20210206","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/bjo.2009.168856","article-title":"Timing of recurrent uveitis in patients with Behcets disease receiving infliximab treatment.","volume":"95","author":"Yamada","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"R34-13-20210206","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","article-title":"Safety and efficacy of infliximab therapy in active Behcets uveitis: an open-label trial.","volume":"29","author":"Al-Rayes","year":"2008","journal-title":"Rheumatol Int"},{"key":"R35-13-20210206","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease.","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R36-13-20210206","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease.","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R37-13-20210206","first-page":"87","article-title":"Effects and safety of infliximab administration in refractory uveoretinitis with Behcets disease.","volume":"114","author":"Tanaka","year":"2010","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"R38-13-20210206","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10792-010-9372-1","article-title":"Effects of infliximab in the treatment of refractory posterior uveitis of Behcets disease after withdrawal of infusions.","volume":"30","author":"Adan","year":"2010","journal-title":"Int Ophthalmol"},{"key":"R39-13-20210206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcets disease refractory to standard immunosuppressive drugs.","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol Int"},{"key":"R40-13-20210206","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcets disease: a comparative 4-week study.","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R41-13-20210206","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/acr.20308","article-title":"Azathioprine in severe uveitis of Behcets disease.","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R42-13-20210206","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/jop.2010.0031","article-title":"Regression of optic disc neovascularization in patients with Behcets uveoretinitis after infliximab therapy.","volume":"26","author":"Kawaguchi","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"R43-13-20210206","first-page":"565","article-title":"Adalimumab: a new modality for Behcets disease Ann Rheum D","volume":"66","author":"Van Laar","year":"2007","journal-title":"is"},{"key":"R44-13-20210206","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Behcets disease.","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye"},{"key":"R45-13-20210206","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","article-title":"Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis.","volume":"31","author":"Takase","year":"2011","journal-title":"Rheumatol Int"},{"key":"R46-13-20210206","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/09273948.2010.483314","article-title":"Clinical experience with adalimumab in the treatment of ocular Behcet disease.","volume":"18","author":"Bawazeer","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"R47-13-20210206","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00417-006-0514-0","article-title":"Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behcets disease.","volume":"245","author":"Atmaca","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R48-13-20210206","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2007.0015","article-title":"Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease.","volume":"23","author":"Tuncer","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"R49-13-20210206","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(94)92549-6","article-title":"Interferon- 2b for refractory ocular Behcets disease.","volume":"343","author":"Feron","year":"1994","journal-title":"Lancet"},{"key":"R50-13-20210206","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","article-title":"Differential efficacy of human recombinant interferon- 2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial.","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R51-13-20210206","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/ICU.0b013e328010ab35","article-title":"Interferon therapy for ocular disease.","volume":"17","author":"Mackensen","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"key":"R52-13-20210206","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kem199","article-title":"Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcets disease.","volume":"46","author":"Guillaume-Czitrom","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R53-13-20210206","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","article-title":"Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcets uveitis refractory to conventional treatments.","volume":"117","author":"Sobaci","year":"2010","journal-title":"Ophthalmology"},{"key":"R54-13-20210206","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon- treatment in patients with severe uveitis due to Behcets disease.","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R55-13-20210206","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis.","volume":"129","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R56-13-20210206","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-008-0057-9","article-title":"Treatment of retinal vasculitis in Behcets disease with rituximab.","volume":"18","author":"Sadreddini","year":"2008","journal-title":"Mod Rheumatol"},{"key":"R57-13-20210206","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcets disease; randomized single-blind control study (pilot study).","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"R58-13-20210206","first-page":"449","article-title":"Retisert: is the new advance in treatment of uveitis a good one Ann P","volume":"41","author":"Mohammad","year":"2007","journal-title":"harmacother"},{"key":"R59-13-20210206","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000318021","article-title":"New developments in corticosteroid therapy for uveitis.","volume":"224","author":"Taylor","year":"2010","journal-title":"Ophthalmologica"},{"key":"R60-13-20210206","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ophtha.2008.10.033","article-title":"Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema.","volume":"116","author":"Taylor","year":"2009","journal-title":"Ophthalmology"},{"key":"R61-13-20210206","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/IAE.0b013e3181d3758a","article-title":"Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis.","volume":"30","author":"Farvardin","year":"2010","journal-title":"Retina"},{"key":"R62-13-20210206","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1756-185X.2010.01531.x","article-title":"Pimecrolimus versus placebo in genital aphthous ulcers of Behcets disease: a randomized double-blind controlled trial.","volume":"13","author":"Chams-Davatchi","year":"2010","journal-title":"Int J Rheum Dis"}],"container-title":["Current Opinion in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICU.0b013e32834bbe91","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:27:29Z","timestamp":1786048049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00055735-201111000-00013"}},"subtitle":["current therapeutic approaches"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/icu.0b013e32834bbe91","relation":{},"ISSN":["1040-8738"],"issn-type":[{"value":"1040-8738","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}